EMA Approves Three Oncology Drugs, Rejects One
This article was originally published in The Pink Sheet Daily
Executive Summary
Cancer drugs had a triumphant day at the European Medicines Agency on July 20, led by Pfizer’s Xalkori, with only one (Celgene’s Istodax) failing to make the grade.